Subject terms
NSCLC, TKI-relapsed
NSCLC
Patients with epidermal growth factor receptor (The combination of a bispecific antibody against EGFR and MET with a tyrosine kinase inhibitor (TKI) in patients with TKI-relapsed, chemotherapy-naive, EGFR-mutated advanced NSCLC is safe and shows preliminary efficacy.